Home Sitemap

Search :
Home >>> About Us >>> Pharmaceuticals >>> Business Innovation
Business Innovation

Business Innovation

Eilaf's main aim is to find new licensors/suppliers for biotechnology, pharmaceutical & medical products for Egypt and the (MENA) region.

Eilaf's goal is to enhance its existence among Pharma business; by providing new products for CVS Oncology & other segments from new licensors.


Eilaf's Business Innovation Team is leaded by

Dr. Haytham Abu-Elfadl M.D., MIBA



Our focus


Eilaf is interested in considering later staged and licensed products. Eilaf intends to grow both organically and by acquisition. Our Business Innovation team focuses on the ‘search’ aspect of the Development strategy, including acquisition of companies and in-licensing of commercialized products. Our team is fully aware of the important aspect of creating long-term productive relationships with our patients/customers & the community we serve will encourage us to fulfill our planned mission.




Eilaf promises to offer:

a. Experienced management for deal finalization.
b. Strong capabilities within the Pharma & medical industry.
c. Constantly exceeding expectations.
d. Effective commercial operation.
e. Product development and regulatory capability.
f. Results oriented thinking.



Our future interests

Eilaf is currently searching for more Biotechnology, Pharmaceutical & Medical technology companies who wish to operate in Egypt &/or MENA region.

Eilaf is also, seeking the opportunity to go in to partnership with pharma companies which already exist in the market and would like to experience larger growth opportunity.

For more information on Eilaf's partnering opportunities, please contact us @ innovation@eilaf.info.



Eilaf Vision

• To be a leading company in the development and commercialization of quality products/ devices in Pharma/medical market.
• Persistently deliver new products to Markets.
• In-Licensing and Marketing proprietary products/devices; and
• Pursuing New Alliances.
• Driving commercial excellent into the MENA region.
• Exceeding patients/clients expectations.
• Adding Branded generic products to our emerging market range, which are sourced externally and marketed under the Eilaf Pharma brand.


To align Eilaf around its strategy is our highest priority



Eilaf Interests


• In-licensing
• Strategic Alliances / Joint Ventures
• Managing Clinical Trials
• Co-marketing
• Co-sales
• Territory: Egypt & MENA (Link to MENA MAP)(Pin point related countries)


Eilaf's Business partners

Eilaf successfully signed an exclusive agreement with Samaritan Pharmaceuticals; where Eilaf became its AGENT.

 For more information log into:www.samaritanpharma.com

Eilaf also signed an exclusive Co-marketing & distribution agree-ment with the leading domestic Co. in the field of Vaccines & blood bank supplies.

• In 2009 Eilaf became the Exclusive AGENT for Ony Inc. USA.